Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001721098 | SCV000223414 | likely benign | not provided | 2019-11-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000461914 | SCV000562840 | likely benign | Brugada syndrome 4 | 2024-01-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000620280 | SCV000737522 | likely benign | Cardiovascular phenotype | 2018-04-17 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002307429 | SCV002600436 | likely benign | not specified | 2022-10-02 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003907536 | SCV004724135 | likely benign | CACNB2-related disorder | 2022-08-22 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |